Patent Assignment
Reel/Frame 048021/0975
Security Interest
Recorded: 2019-01-07
Pages: 20
Assignors
COHERUS BIOSCIENCES, INC.
Executed: 2019-01-07
COHERUS INTERMEDIATE CORP.
Executed: 2019-01-07
INTEKRIN THERAPEUTICS INC.
Executed: 2019-01-07
Assignee
HCR COLLATERAL MANAGEMENT, LLC, AS ADMINISTRATIVE AGENT
300 ATLANTIC STREET, SUITE 600, STAMFORD, CONNECTICUT, 06901
Covered Properties
(71)
Etanercept Formulations Stabilized with Amino Acids
Etanercept Formulations Stabilized with Metal Ions
Etanercept Formulations Stabilized with Sodium Chloride
Etanercept Formulations Stabilized with Meglumine
Etanercept Formulations Stabilized with Xylitol
Etanercept Formulations Stabilized with Combinations of Sugars and Polyols
Solid Pharmaceutical Compositions of Ppary Modulator
Ppar Gamma Agonists for Treatment of Multiple Sclerosis
Perfusion Method for Manufacturing Etanercept
Etanercept Formulations Exhibiting Marked Reduction in Sub-Visible Particles
Stable Aqueous Formulations of Etanercept
Method of Manufacturing a Protein by Perfusion in Media with a Low Amino Acid Concentration
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Ppar Gamma Agonists for Treatment of Multiple Sclerosis
Correctly Folded Etanercept Composition
Methods for Making Recombinant Proteins
Patent:
10,435,464 →
Application:
14/845,440 →
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Methods for the Treatment of Nonalcoholic Fatty Liver Disease and/or Lipodystrophy
Etanercept Formulations Stabilized with Combinations of Sugars and Polyols
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Etanercept Formulations Stabilized with Xylitol
High Concentration Formulations of Adalimumab
Patent:
11,229,702 →
Application:
15/337,519 →
Stable Adalimumab Compositions and Methods of Their Use
Patent:
11,583,584 →
Application:
15/337,845 →
Stable Aqueous Formulations of Adalimumab
Ppar Gamma Agonists for Treatment of Multiple Sclerosis
Method of Filling a Container with No Headspace
Antidiabetic Solid Pharmaceutical Compositions
Application:
15/620,513 →
Publication:
US 2017/0273969
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Etanercept Formulations Stabilized with Xylitol
Correctly Folded Etanercept in High Purity and Excellent Yield
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Syringe Containing Stable Aqueous Formulations of Adalimumab
Methods of Manufacturing Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Application:
15/730,399 →
Publication:
US 2018/0028655
Stable Aqueous Formulations of Adalimumab
Application:
15/730,425 →
Publication:
US 2018/0028656
Stable Aqueous Formulations of Adalimumab
Application:
15/730,445 →
Publication:
US 2018/0028657
Stable Aqueous Formulations of Natalizumab
Application:
15/745,365 →
Publication:
US 2021/0322549
Method of Reducing Immunogenicity of Drug Products
Application:
15/793,976 →
Publication:
US 2018/0043020
Etanercept Formulations Stabilized with Metal Ions
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Etanercept Formulations Stabilized with Combinations of Sugars and Polyols
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Method of Manufacturing a Protein by Perfusion in Media with a Low Amino Acid Concentration
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Aflibercept
Application:
62/640,411 →
Methods of Treating Subjects with an Elevated Neurofilament Light Chain Level
Application:
62/651,653 →
Methods for Producing Recombinant Proteins
Application:
62/776,880 →
Related Assignments
(15)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 8, 2013
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 029590/0337 →
Assignment of Assignor's Interest
Jan 8, 2013
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 029590/0561 →
Assignment of Assignor's Interest
Jan 8, 2013
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 029590/0523 →
Assignment of Assignor's Interest
Jan 8, 2013
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 029590/0436 →
Assignment of Assignor's Interest
Jan 8, 2013
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 029590/0397 →
Assignment of Assignor's Interest
Jan 8, 2013
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 029590/0367 →
Assignment of Assignor's Interest
Feb 6, 2014
From: WEINSTEIN, DAVID
To: INTEKRIN THERAPEUTICS, INC.
Reel/Frame 032166/0840 →
Assignment of Assignor's Interest
Mar 4, 2015
From: MANNING, MARK; MURPHY, BRIAN; FARRAR, DOUGLAS; HERMAN, ALAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 035083/0126 →
Assignment of Assignor's Interest
Sep 24, 2015
From: PUCHACZ, ELA; GROVE, JAMES RUSSELL
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 036643/0917 →
Assignment of Assignor's Interest
Jan 7, 2016
From: MANNING, MARK; PAYNE, ROBERT
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 037428/0498 →
Assignment of Assignor's Interest
Jan 13, 2016
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 037472/0665 →
Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975
Jan 11, 2022
From: HCR COLLATERAL MANAGEMENT, LLC
To: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
Reel/Frame 058692/0665 →
Security Interest
Mar 18, 2022
From: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 059436/0055 →
Security Interest
May 8, 2024
From: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.; SURFACE ONCOLOGY, LLC
To: ANKURA TRUST COMPANY, LLC
Reel/Frame 067348/0160 →
Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055
May 9, 2024
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
Reel/Frame 067378/0256 →